Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Core Insights - Aclarion, Inc. has published a CEO Shareholder Letter outlining strategic progress and upcoming catalysts for 2026, emphasizing the company's focus on expanding the adoption of its Nociscan platform and enhancing clinical evidence and reimbursement initiatives [2][3][4] Financial Performance - For the three months ended May 31, 2024, Aclarion reported total revenue of $5,031,000, a 40% increase from $3,603,000 in the same period of 2023 [1] - Revenue breakdown includes: - Fluxing Systems: $134,000 (2% of total), down 43% from $236,000 (6% of total) in 2023 - Integrated Coating Systems: $747,000 (15% of total), up 142% from $309,000 (9% of total) in 2023 - Multi-Axis Coating Systems: $2,664,000 (53% of total), up 51% from $1,763,000 (49% of total) in 2023 - OEM Systems: $332,000 (7% of total), up 21% from $274,000 (8% of total) in 2023 - Spare Parts, Services, and Other: $1,154,000 (23% of total), up 13% from $1,021,000 (28% of total) in 2023 [1] Strategic Initiatives - The company is pursuing reimbursement coverage from regional insurance providers in the U.S. as a critical step towards broader payer adoption [2] - Aclarion is advancing its ongoing CLARITY clinical trial, with initial readout expected in Q4 2026, and is expanding commercial engagement with physicians and imaging centers [3][4] - The company maintains a strong balance sheet with a cash runway extending into 2028, supporting its strategic initiatives [2][3]